Antiphospholipid Syndrome Risk Evaluation

dc.contributor.authorVilhena, João
dc.contributor.authorVicente, Henrique
dc.contributor.authorMartins, M. Rosário
dc.contributor.authorGrañeda, José M.
dc.contributor.authorCaldeira, Filomena
dc.contributor.authorGusmão, Rodrigo
dc.contributor.authorNeves, João
dc.contributor.authorNeves, José
dc.contributor.editorRocha, Álvaro
dc.contributor.editorCorreia, Ana Maria
dc.contributor.editorAdeli, Hojjat
dc.contributor.editorReis, Luís
dc.contributor.editorTeixeira, Marcelo
dc.date.accessioned2016-03-16T17:22:11Z
dc.date.available2016-03-16T17:22:11Z
dc.date.issued2016
dc.description.abstractThe antiphospholipid syndrome is an acquired autoimmune disorder produced by high titers of antiphospholipid antibodies that cause both arterial and veins thrombosis as well as pregnancy-related complications and morbidity, as clinical manifestations. This autoimmune hypercoagulable state, often associated with coronary artery disease and recurrent Acute Myocardium Infraction, has severe consequences for the patients, being one of the main causes of thrombotic disorders and death. Therefore, it is extremely important to be preventive; being aware of how probable is to have that kind of syndrome. Despite the updated of the APS classification published as Sydney criteria, diagnosis of this syndrome remains challenging. Further research on clinically relevant antibodies and standardization of their quantification are required to improve clinical risk assessment in APS. This work will focus on the development of a diagnosis support system to antiphospholipid syndrome, built under a formal framework based on Logic Programming, in terms of its knowledge representation and reasoning procedures, complemented with an approach to computing grounded on Artificial Neural Networks. The proposed model allowed to improve the diagnosis, classifying properly the patients that really presented this pathology (sensitivity about 92%) as well as classifying the absence of APS (specificity ranging from 89% to 94%).por
dc.identifier.authoremailjmvilhena@gmail.com
dc.identifier.authoremailhvicente@uevora.pt
dc.identifier.authoremailmrm@uevora.pt
dc.identifier.authoremailgraneda1@sapo.pt
dc.identifier.authoremailfilomenacaldeira1@gmail.com
dc.identifier.authoremailgusmao.rodrigo@gmail.com
dc.identifier.authoremailjoaocpneves@gmail.com
dc.identifier.authoremailjneves@di.uminho.pt
dc.identifier.citationVilhena, J., Vicente, H., Martins, M. R., Grañeda, J., Caldeira, F., Gusmão, R., Neves, J. & Neves, J. Antiphospholipid Syndrome Risk Evaluation. In Á. Rocha, A.M. Correia, H. Adeli, L.P. Reis & M.M. Teixeira, Eds., New Advances in Information Systems and Technologies – Vol. 1, Advances in Intelligent Systems and Computing, Vol. 444, pp. 157–167, Springer International Publishing, Cham, Switzerland, 2016.por
dc.identifier.doi10.1007/978-3-319-31232-3_15por
dc.identifier.isbn978-3-319-31231-6
dc.identifier.issn2194-5357
dc.identifier.sharewithICAAM; DQUIpor
dc.identifier.urihttp://link.springer.com/chapter/10.1007/978-3-319-31232-3_15
dc.identifier.urihttp://hdl.handle.net/10174/18150
dc.language.isoporpor
dc.publisherSpringer International Publishingpor
dc.rightsopenAccesspor
dc.subjectAntiphospholipid Syndromepor
dc.subjectLogic Programmingpor
dc.subjectArtificial Neural Networkspor
dc.subjectKnowledge Representation and Reasoningpor
dc.titleAntiphospholipid Syndrome Risk Evaluationpor
dc.typebookPartpor

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2016_WorldCIST_2016_RD.pdf
Size:
51.89 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
3.89 KB
Format:
Item-specific license agreed upon to submission
Description: